Dr Michael Jacobs…He said Ms Cafferkey was treated with blood plasma from an Ebola survivor and an experimental treatment drug closely related drug to ZMapp, which UK nurse Will Pooley was treated with after he contracted Ebola.
Note: You would think a success of a ZMapp clone would be cause for a public announcement. Will they be keeping Blood Plasma stock from Ms Cafferkey for future patients?
Phase 3 Ebola Vaccine Trials (Phase 2 skipped)
Prof Jonathan Ball, Professor of Molecular Virology, University of Nottingham, said: “This is really good news – the team at the Royal Free have done a fantastic job.
“We will never know if investigational drugs and convalescent plasmas contributed to her improvement, but it does once again highlight the huge benefits that modern well-resourced critical care interventions can bring to those suffering from severe Ebolavirus infection.”
Investigational drugs? Trial drugs?
Dr Martin Deahl says, “We were all ushered into a suite of rooms at Border Control but they were very cramped. If no one had come into close contact with the poor nurse on the flight then they certainly would have done at this point.
“We were told we could go home using public transport but then told not to use public transport when we got home or to go into crowded places. Some people had to catch a tube train into London, if that isn’t a crowded place then I don’t what is.”
Ms Cafferkey had been part of a team of medical volunteers deployed to Sierra Leone by the UK government in November.
The 39-year-old is being treated with an experimental anti-viral drug at the Royal Free Hospital in Hampstead.
Ms Cafferkey’s is the second UK case of Ebola. Nurse William Pooley recovered from the disease in September after also being treated at the Royal Free Hospital.